Sprout Pharmaceuticals receives FDA Approval of ADDYI™!!!!!!!!!!!!! First-ever FDA-approved treatment for women’s most common form of sexual dysfunction, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is a persistent absence of sexual thoughts, fantasies, responsiveness and willingness to engage in sexual activity that causes personal or relationship distress and cannot be accounted for by another medical condition or substance. Addyi (pronounced add-ee), known generically as Flibanserin, is the first drug that acts on brain chemicals that affect mood and appetite. It is a once-daily, non-hormonal pill. It is estimated that 8 to 14 percent of women ages 20 to 49 have the condition, or about 5.5 to 8.6 million U.S. women. I understand that doctors must rule out many issues before diagnosing the condition, including relationship issues, medical problems, depression and mood disorders. Hmmmmmmmmmmmmmmmmm, I was just wandering if these same issues also have to be ruled out before the “blue pill” is prescribed for men????????????
Embracing authenticity during menopause is liberating! It’s a journey of self-discovery, where buried passions and dreams resurface.